| Protiva partnered with [[Roche]] subsidiary [[Alnylam Pharmaceuticals]] in [[united_states_of_america:massachussetts:Cambridge]], [[united_states_of_america:Massachusetts]] to collaboratively develop products using RNAi to inhibit, or “turn off”, target genes (compared to [[:mRNA]], which turns on production of [[:proteins]]), which bore fruit in a 2006 study demonstrating success silencing genes in monkeys.((Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Röhl, I., Seiffert, S., Shanmugam, S., & Sood, V. (2006). //RNAi-mediated gene silencing in non-human primates.// Nature, 441(7089), 111–114. https://doi.org/10.1038/nature04688)) | Protiva partnered with [[Roche]] subsidiary [[Alnylam Pharmaceuticals]] in [[united_states_of_america:massachussetts:Cambridge]], [[united_states_of_america:Massachusetts]] to collaboratively develop products using RNAi to inhibit, or “turn off”, target genes (compared to [[:mRNA]], which turns on production of [[:proteins]]), which bore fruit in a 2006 study demonstrating success silencing genes in monkeys.((Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Röhl, I., Seiffert, S., Shanmugam, S., & Sood, V. (2006). //RNAi-mediated gene silencing in non-human primates.// Nature, 441(7089), 111–114. https://doi.org/10.1038/nature04688)) |
| The [[:Business Development Bank of Canada]] (BDC) participated in multiple rounds of investing into Protiva, including $4,950,000 in 2006 and $3,300,000 in 2007.((laura998. (2018). //Protiva Biotherapeutics.// RaisedToday. https://archive.ph/AlJnY)) The BDC is wholly owned by the [[:Government of Canada]], meaning the federal government has a potential financial conflict of interest in the [[:COVID-19 vaccines]] that laster used lipid nanoparticle licenses associated with Protiva. | The [[:Business Development Bank of Canada]] (BDC) participated in multiple rounds of investing into Protiva, including $4,950,000 in 2006 and $3,300,000 in 2007.((laura998. (2018). //Protiva Biotherapeutics.// RaisedToday. https://archive.ph/AlJnY)) The BDC is wholly owned by the [[:Government of Canada]], meaning the federal government has a potential financial conflict of interest in the [[:COVID-19 vaccines|COVID-19 vaccines]] that later used lipid nanoparticle licenses associated with Protiva. |
| On March 30, 2008, Protiva announced it was combining its business with [[Tekmira Pharmaceuticals]], reuniting the intellectual property that had become scattered across several startups out of UBC. The new joint company signed a new deal with [[Alnylam Pharmaceuticals]] to allow access to their lipid nanoparticle patents - a key component of achieving their self-described “Alnylam 2020” strategy.((//Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics announce business combination to create new company focused on RNAi delivery and therapeutics.// (2008, March 31). Fierce Biotech. https://www.fiercebiotech.com/biotech/tekmira-pharmaceuticals-corporation-and-protiva-biotherapeutics-announce-business)) ((Lindenboom, C. R., & Brodsky, J. (2021, January 10). //Alnylam launches “Alnylam P5x25” strategy for planned transition to a top five biotech in market capitalization over next five years.// Business Wire; Berkshire Hathaway. https://archive.ph/0wJ2n)) | On March 30, 2008, Protiva announced it was combining its business with [[Tekmira Pharmaceuticals]], reuniting the intellectual property that had become scattered across several startups out of the [[:University of British Columbia]] (UBC). The new joint company signed a new deal with [[Alnylam Pharmaceuticals]] to allow access to their lipid nanoparticle patents - a key component of achieving their self-described “Alnylam 2020” strategy.((//Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics announce business combination to create new company focused on RNAi delivery and therapeutics.// (2008, March 31). Fierce Biotech. https://www.fiercebiotech.com/biotech/tekmira-pharmaceuticals-corporation-and-protiva-biotherapeutics-announce-business)) ((Lindenboom, C. R., & Brodsky, J. (2021, January 10). //Alnylam launches “Alnylam P5x25” strategy for planned transition to a top five biotech in market capitalization over next five years.// Business Wire; Berkshire Hathaway. https://archive.ph/0wJ2n)) |
